Tscan Therapeutics Corporate Bonds and Leverage Analysis

TCRX Stock  USD 4.77  0.13  2.80%   
Tscan Therapeutics holds a debt-to-equity ratio of 0.039. At this time, Tscan Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Short Term Debt is likely to rise to about 10.3 M in 2024, whereas Net Debt is likely to drop (43 M) in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Tscan Therapeutics' Earnings Per Share (EPS).

Asset vs Debt

Equity vs Debt

Tscan Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Tscan Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Tscan Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Tscan Therapeutics' stakeholders.
For most companies, including Tscan Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Tscan Therapeutics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Tscan Therapeutics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book
1.1113
Book Value
4.294
Operating Margin
(31.10)
Return On Assets
(0.23)
Return On Equity
(0.56)
Total Current Liabilities is likely to drop to about 19.4 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 166.9 M in 2024
  
Check out the analysis of Tscan Therapeutics Fundamentals Over Time.
For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.
View Bond Profile
Given the importance of Tscan Therapeutics' capital structure, the first step in the capital decision process is for the management of Tscan Therapeutics to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Tscan Therapeutics to issue bonds at a reasonable cost.

Tscan Therapeutics Bond Ratings

Tscan Therapeutics financial ratings play a critical role in determining how much Tscan Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Tscan Therapeutics' borrowing costs.
Piotroski F Score
4
PoorView
Beneish M Score
(4.66)
Unlikely ManipulatorView

Tscan Therapeutics Debt to Cash Allocation

As Tscan Therapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. Tscan Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Tscan Therapeutics currently holds 92.43 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Tscan Therapeutics has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Tscan Therapeutics' use of debt, we should always consider it together with its cash and equity.

Tscan Therapeutics Total Assets Over Time

Tscan Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Tscan Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Tscan Therapeutics Debt Ratio

    
  13.0   
It appears most of the Tscan Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Tscan Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Tscan Therapeutics, which in turn will lower the firm's financial flexibility.

Tscan Therapeutics Corporate Bonds Issued

Tscan Short Long Term Debt Total

Short Long Term Debt Total

97.05 Million

At this time, Tscan Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year.

Understaning Tscan Therapeutics Use of Financial Leverage

Understanding the structure of Tscan Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Tscan Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last ReportedProjected for Next Year
Short and Long Term Debt Total92.4 M97.1 M
Net Debt-40.9 M-43 M
Short Term Debt9.8 M10.3 M
Long Term Debt26.7 M22.4 M
Short and Long Term DebtM2.7 M
Net Debt To EBITDA 0.51  0.49 
Debt To Equity 0.22  0.21 
Interest Debt Per Share 0.56  0.59 
Debt To Assets 0.12  0.13 
Long Term Debt To Capitalization 0.15  0.14 
Total Debt To Capitalization 0.18  0.29 
Debt Equity Ratio 0.22  0.21 
Debt Ratio 0.12  0.13 
Cash Flow To Debt Ratio(1.84)(1.94)
Please read more on our technical analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

What is Financial Leverage?

Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.

Leverage and Capital Costs

The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.

Benefits of Financial Leverage

Leverage provides the following benefits for companies:
  • Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
  • It provides a variety of financing sources by which the firm can achieve its target earnings.
  • Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.
By borrowing funds, the firm incurs a debt that must be paid. But, this debt is paid in small installments over a relatively long period of time. This frees funds for more immediate use in the stock market. For example, suppose a company can afford a new factory but will be left with negligible free cash. In that case, it may be better to finance the factory and spend the cash on hand on inputs, labor, or even hold a significant portion as a reserve against unforeseen circumstances.

The Risk of Financial Leverage

The most obvious and apparent risk of leverage is that if price changes unexpectedly, the leveraged position can lead to severe losses. For example, imagine a hedge fund seeded by $50 worth of investor money. The hedge fund borrows another $50 and buys an asset worth $100, leading to a leverage ratio of 2:1. For the investor, this is neither good nor bad -- until the asset price changes. If the asset price goes up 10 percent, the investor earns $10 on $50 of capital, a net gain of 20 percent, and is very pleased with the increased gains from the leverage. However, if the asset price crashes unexpectedly, say by 30 percent, the investor loses $30 on $50 of capital, suffering a 60 percent loss. In other words, the effect of leverage is to increase the volatility of returns and increase the effects of a price change on the asset to the bottom line while increasing the chance for profit as well.